The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review.
Khalid Almutairi, Johannes Nossent, David Preen...
https://pubmed.ncbi.nlm.nih.gov/33175207/Actively Recruiting
Led by Foundation University Islamabad · Updated on 2026-02-05
110
Participants Needed
2
Research Sites
13 weeks
Total Duration
This research aims to study the pharmacogenetics of leflunomide in treating rheumatoid arthritis RA among Pakistani patients. RA is an autoimmune disease causing inflammation, and leflunomide is a second-line drug used when first-line treatments fail. The study plans to explore the relationship between genetic variations in the DHODH and ABCG2 genes and the drugs effectiveness and side effects. This could help tailor treatment to individual patients based on their genetics. Participants taking leflunomide as their only disease-modifying anti-rheumatic drug DMARD will be enrolled. Blood samples will be collected to extract DNA and identify genetic markers called single nucleotide polymorphisms SNPs. Patients will be followed for six months with visits three months apart to evaluate disease activity using the DAS28 score, ultrasonography, and various blood tests including liver function, ESR, CRP, and anti-CCP antibodies. The study will analyze how these genetic markers relate to treatment results and side effects. During the study, participants will have clinical assessments at baseline, three months, and six months, including monitoring for side effects such as nausea, liver toxicity, and infections. Researchers will collect detailed data on symptoms, laboratory tests, and imaging results. The main outcome is the change in disease activity score DAS28 over two years, along with identification of genetic factors affecting drug response and liver toxicity. This information aims to improve treatment decisions for RA patients in Pakistan.
CONDITIONS
Pharmacogenetics of Leflunomide in the Management of Rheumatoid Arthritis
D
Dr. Zarafshan Bader, MPhil, MBBS
D
Dr Abida Shaheen, PHD, MBBS, FAIMER FELLOW
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Foundation University Islamabad
Lead Sponsor
Shifa Tameer-e-Millat University
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 6 months
Participants take leflunomide as a single DMARD for rheumatoid arthritis and are observed for treatment efficacy and toxicity.
Visits at baseline, 3 months, and 6 months
Duration - Up to 2 years
Participants continue to be monitored for clinical outcomes and adverse effects after treatment assessment periods.
Periodic visits for assessments over 2 years
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Khalid Almutairi, Johannes Nossent, David Preen...
https://pubmed.ncbi.nlm.nih.gov/33175207/Harshad Devarbhavi, Marwan Ghabril, Huiman Barnhart...
https://pubmed.ncbi.nlm.nih.gov/35129282/Allan Wailoo, Emma S Hock, Matt Stevenson...
https://pubmed.ncbi.nlm.nih.gov/29206093/Petra Bohanec Grabar, Blaz Rozman, Matija Tomsic...
https://pubmed.ncbi.nlm.nih.gov/18496682/Daniel Aletaha, Tuhina Neogi, Alan J Silman...
https://pubmed.ncbi.nlm.nih.gov/20872595/Ashley M Hopkins, Michael D Wiese, Susanna M Proudman...
https://pubmed.ncbi.nlm.nih.gov/26331989/Petra Bohanec Grabar, Iztok Grabnar, Blaz Rozman...
https://pubmed.ncbi.nlm.nih.gov/19581389/P Bohanec Grabar, B Rozman, D Logar...
https://pubmed.ncbi.nlm.nih.gov/19605743/Lesley Davila, Prabha Ranganathan
https://pubmed.ncbi.nlm.nih.gov/21826093/Foundation University Islamabad
Lead Sponsor
Shifa Tameer-e-Millat University
Collaborating Sponsor